Nonalcoholic Steatohepatitis Treatment Market: By Product Type, Pioglitazone, and Others), By Distribution Channel, and Region Forecast 2019-2030
Nonalcoholic Steatohepatitis (NASH) Treatment Market size was valued at US$ 1,352.1 million in 2023 and is poised to grow at a CAGR of 36.3% from 2024 to 2030. Nonalcoholic steatohepatitis (NASH) treatment or fatty liver disease develop in the nonalcoholic humans that causes the liver damage which is diagnostically similar to alcoholic hepatitis. Nonalcoholic steatohepatitis may also causes due to glucose intolerance, dyslipidemia, and obesity. Currently a few drugs are available in the market for the treatment of nonalcoholic steatohepatitis treatment.
The non-alcoholic steatohepatitis (NASH) market is estimated to rise by double digits over the forecast period, owing to rising demand for optimum NASH therapies, an increase in the prevalence of NASH, and the planned launch of pipeline medications. Furthermore, an increase in the prevalence of diabetes and obesity, as well as increased awareness of NASH in developing regions, is expected to boost market growth during the forecast period.
However, the industry is expected to be constrained by poor disease diagnosis and a lack of ideal diagnostic techniques. The leading players in the non-alcoholic steatohepatitis (NASH) industry will find profitable prospects in Asia-Pacific. Growth in diagnostic techniques, rapid rise in prevalence of NASH, economic expansion, and increased demand for NASH therapies are some of the factors driving market growth in Asia-Pacific. Other factors such as rising healthcare infrastructure, emerging economies, and an increasing rate of diagnosis are likely to aid the expansion of the Asia-Pacific market. Furthermore, rising healthcare awareness in emerging nations such as India and China is propelling the industry forward.
Study Period
2024-2030Base Year
2023CAGR
36.3%Largest Market
North AmericaFastest Growing Market
Europe
Increase in the prevalence of metabolic disorders such as diabetes and dyslipidemia are expected to drive the NASH Treatment Market. Moreover, rise in R&D for the innovation of novel therapeutics for NASH disease, promising pipeline products, and change in lifestyle are anticipated to boost the nonalcoholic steatohepatitis treatment market over the forecast period. However, lack of efficient disease diagnosis procedures in early stage, poor understanding of disease pathophysiology, and large medical unmet need may impede the growth of market.
Geographically, global nonalcoholic steatohepatitis (NASH) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America market growth driven by increase in the prevalence of NASH disease due to rise in obesity and metabolic disorders (according to American Liver Foundation, approximately 12% of total population has NASH and 3% has advanced liver fibrosis due to NASH) and change in lifestyle are anticipated to fuel the market.
Europe market expected to exhibit lucrative growth due to increase in the R&D for the innovation of newer drugs, rise in prevalence of NASH due to metabolic disorders, and increase in healthcare expenditure. However, a significant growth rate observed in Asia Pacific market owing to entry of market players into Asia Pacific region, large patient pool, and rise in healthcare expenditure are expected to bolster the market in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 1,352.1 million |
|
Market CAGR |
36.3% |
|
By Product Type |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
nonalcoholic steatohepatitis nash treatment market size was valued at US$ 1,352.1 million in 2023 and is projected to grow at a CAGR of 36.3% by 2030.
Obesity and type 2 diabetes are directly linked with increased chances of NASH.
| 1. Executive Summary |
| 2. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Introduction |
| 2.1.Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Taxonomy |
| 2.2.Global Nonalcoholic Steatohepatitis (NASH) Treatment Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Simtuzumab and Liraglutide |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. GFT 505 |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vitamin E |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Obeticholic Acid (INT-747) |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Pioglitazone |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Online Pharmacies |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Retail Pharmacies |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Nonalcoholic Steatohepatitis (NASH) Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. North America Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Simtuzumab and Liraglutide |
| 8.1.2.GFT 505 |
| 8.1.3.Vitamin E |
| 8.1.4.Obeticholic Acid (INT-747) |
| 8.1.5.Pioglitazone |
| 8.1.6.Others |
| 8.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacies |
| 8.2.2.Online Pharmacies |
| 8.2.3.Retail Pharmacies |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9. Europe Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Simtuzumab and Liraglutide |
| 9.1.2.GFT 505 |
| 9.1.3.Vitamin E |
| 9.1.4.Obeticholic Acid (INT-747) |
| 9.1.5.Pioglitazone |
| 9.1.6.Others |
| 9.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Online Pharmacies |
| 9.2.3.Retail Pharmacies |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10. Asia Pacific (APAC) Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Simtuzumab and Liraglutide |
| 10.1.2.GFT 505 |
| 10.1.3.Vitamin E |
| 10.1.4.Obeticholic Acid (INT-747) |
| 10.1.5.Pioglitazone |
| 10.1.6.Others |
| 10.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Online Pharmacies |
| 10.2.3.Retail Pharmacies |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11. Middle East and Africa (MEA) Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Simtuzumab and Liraglutide |
| 11.1.2.GFT 505 |
| 11.1.3.Vitamin E |
| 11.1.4.Obeticholic Acid (INT-747) |
| 11.1.5.Pioglitazone |
| 11.1.6.Others |
| 11.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Online Pharmacies |
| 11.2.3.Retail Pharmacies |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12. Latin America Nonalcoholic Steatohepatitis (NASH) Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Simtuzumab and Liraglutide |
| 12.1.2.GFT 505 |
| 12.1.3.Vitamin E |
| 12.1.4.Obeticholic Acid (INT-747) |
| 12.1.5.Pioglitazone |
| 12.1.6.Others |
| 12.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Online Pharmacies |
| 12.2.3.Retail Pharmacies |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Zydus Cadila (India) |
| 13.2.2.Genfit SA (France) |
| 13.2.3.AstraZeneca Plc (UK) |
| 13.2.4.Gilead Sciences, Inc. (U.S.) |
| 13.2.5.Conatus Pharmaceuticals, Inc. (U.S.) |
| 13.2.6.Galmed Pharmaceuticals Ltd (Israel) |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
